• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

The PREVENT trial: eculizumab reduces relapse risk in patients with neuromyelitis optica and aquaporin-4 antibodies

byDayton McMillan
August 17, 2019
in Chronic Disease, Neurology
Reading Time: 3 mins read
1
Share on FacebookShare on Twitter

1. In this randomized control trial of neuromyelitis optica spectrum disorder (NMOSD) patients with aquaporin-4 antibodies (AQP4-IgG), those randomized to receive the eculizumab complement inhibitor experienced a lower relapse rate over 24 months than placebo treated patients.

2. Eculizumab patients more commonly experienced upper respiratory tract infections (URI) and headaches.

Evidence Rating Level: 1 (Excellent)  

Study Rundown: Neuromyelitis optica spectrum disorder (NMOSD) is a recurrent autoimmune disorder mainly characterized by optic neuritis and myelitis. Rituximab is an approved treatment to prevent relapses but is not effective for all patients. AQP4 is a protein in the central nervous system which a majority of NMOSD patients have IgG antibodies to, and the AQP4-IgG complex leads to complement activation facilitating relapses. Eculizumab is a complement inhibitor thought to be efficacious at ultimately reducing NMOSD relapse events. The PREVENT trial (Prevention of Relapses in Neuromyelitis Optica) evaluated a primary outcome of first adjudicated relapse in placebo or eculizumab treated patients and found relapses occurred less in treated patients. Eculizumab treated patients had disability scores that trended towards improvement from baseline, though they did experience more URIs and headaches than placebo patients. One death due to pulmonary empyema occurred in an eculizumab patient.

This randomized control trial suggests notable efficacy of eculizumab in preventing NMOSD relapses in a major subpopulation of patients. While the efficacy data is marked, the study is limited by the difficulties in interpreting an NMOSD relapse which ultimately stopped the trial.

Click to read the study in NEJM

Relevant Reading: Failure of natalizumab to prevent relapses in neuromyelitis optica

RELATED REPORTS

#VisualAbstract: Adding four doses of rituximab did not significantly improve event-free survival over standard of care in acute lymphoblastic leukaemia

Biosimilar drugs undergo rigorous clinical testing and yield comparable outcomes to biologics

Belimumab after rituximab reduces risk for severe flare in systemic lupus erythematosus

In-Depth [randomized controlled trial]: This phase 3, multinational, double-blind, placebo-controlled, randomized trial enrolled patients between 2014 and 2017. Eligible patients were adults with NMOSD, AQP4-IgG positive, were not severely disabled, and had a history of multiple recent NMOSD relapses. Those who received recent rituximab or other immunotherapies were ineligible. Patients were randomized to an eculizumab (n=96) or placebo (n=47) group. Patients were dose escalated up to 1200mg eculizumab biweekly by the time the trial began. The primary end point was time to first adjudicated relapse, with relapses determined by a 3-physician committee based on data gathered by treating physicians. Prior to randomization, the mean annualized relapse rate was 1.99 for all patients. More eculizumab patients discontinued the trial (17% vs 6%). Adjudicated relapse occurred in 3% (3/96) and 43% (20/47) of the eculizumab and placebo groups, respectfully (hazard ratio, 0.06; 95% confidence interval [CI], 0.02 to 0.20; P<0.001). In treating physician determined relapse, 15% and 62% of eculizumab and placebo groups experienced an event (hazard ratio, 0.18; 95% CI, 0.10 to 0.34; P<0.001). Disagreements between treating and committee physicians on which events were considered relapses resulted in trial stoppage. Eculizumab patients had a lower annualized rate of relapse (0.02 vs 0.35, respectfully; P<0.001). The change in disability score from baseline trended towards improvement in the treatment group but was not significant (least-squares mean difference, -0.29; 95% CI, -0.59 to 0.01). URIs and headaches were more common in the treatment group. One treatment patient who was on concurrent azathioprine died due to pulmonary empyema.

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc

Tags: aquaporin-4 antibodies (AQP4-IgG)Eculizumabneuromyelitis optica spectrum disorder (NMOSD)rituximab
Previous Post

Excess body fat is a major risk factor for premature death among Hispanic patients

Next Post

Quick Take: Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy

RelatedReports

#VisualAbstract: Adding four doses of rituximab did not significantly improve event-free survival over standard of care in acute lymphoblastic leukaemia
StudyGraphics

#VisualAbstract: Adding four doses of rituximab did not significantly improve event-free survival over standard of care in acute lymphoblastic leukaemia

April 8, 2022
Quick Take: Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial
Oncology

Biosimilar drugs undergo rigorous clinical testing and yield comparable outcomes to biologics

February 22, 2022
Quick Take: Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study
Chronic Disease

Belimumab after rituximab reduces risk for severe flare in systemic lupus erythematosus

November 15, 2021
#VisualAbstract Lenalidomide in combination with R-CHOP is effective in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma
StudyGraphics

#VisualAbstract Lenalidomide in combination with R-CHOP is effective in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma

November 12, 2021
Next Post
Maternal vaccination during pregnancy not associated with infant hospitalization, mortality

Quick Take: Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy

Poor olfaction linked to increased mortality in older adults

Quick Take: Association of hearing loss with dementia

Risk of autism in offspring linked to maternal pregestational diabetes and severe obesity

Quick Take: Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES)

Please login to join discussion

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Hybrid immunity protects against infection with omicron variant of COVID-19
  • #VisualAbstract: Tirzepatide Once Weekly for the Treatment of Obesity
  • Wellness Check: Sleep
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.